Omeros Corporation (NASDAQ:OMER) Sees Significant Growth in Short Interest

Omeros Corporation (NASDAQ:OMER) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totaling 16,429,140 shares, a growth of 24.0% from the December 31st total of 13,247,185 shares. Based on an average trading volume of 3,516,886 shares, the short-interest ratio is presently 4.7 days. Currently, 26.6% of the company’s shares are sold short. Currently, 26.6% of the company’s shares are sold short. Based on an average trading volume of 3,516,886 shares, the short-interest ratio is presently 4.7 days.

Insider Activity at Omeros

In related news, CAO David J. Borges sold 30,000 shares of Omeros stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total transaction of $369,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 12.90% of the company’s stock.

Hedge Funds Weigh In On Omeros

Hedge funds have recently made changes to their positions in the business. Farther Finance Advisors LLC raised its holdings in shares of Omeros by 16.5% in the fourth quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 1,004 shares during the last quarter. Russell Investments Group Ltd. increased its stake in Omeros by 113.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 5,677 shares during the last quarter. B. Riley Wealth Advisors Inc. acquired a new stake in Omeros in the 2nd quarter valued at $32,000. Tower Research Capital LLC TRC lifted its position in Omeros by 829.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 11,971 shares in the last quarter. Finally, Sei Investments Co. acquired a new position in shares of Omeros during the 2nd quarter worth about $40,000. 48.79% of the stock is owned by institutional investors.

Omeros Stock Performance

NASDAQ OMER traded up $0.10 on Tuesday, reaching $11.82. The company had a trading volume of 1,125,784 shares, compared to its average volume of 2,398,594. The company’s fifty day moving average is $12.09 and its 200-day moving average is $7.74. The firm has a market capitalization of $838.04 million, a price-to-earnings ratio of -5.85 and a beta of 2.44. Omeros has a 1-year low of $2.95 and a 1-year high of $17.65.

Omeros (NASDAQ:OMER) last released its quarterly earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.39. On average, research analysts forecast that Omeros will post -3.09 earnings per share for the current year.

Analyst Upgrades and Downgrades

OMER has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a research note on Thursday, January 22nd. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Wednesday, October 15th. HC Wainwright lifted their price target on shares of Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Wall Street Zen cut shares of Omeros from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Finally, D. Boral Capital reiterated a “buy” rating and set a $36.00 target price on shares of Omeros in a report on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $40.33.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.